Strategic Diagnostics Inc. currently provides biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental, and life science applications. Francis DiNuzzo has been with Strategic Diagnostics as their Executive Vice President and Chief Commercial Officer since February of 2008. “He has served us well in his role as interim CEO, and we have determined that Fran is the right person to lead the company forward,” said Grover C. Wrenn, chairman of the Board.
This promotion has been welcomed by Mr. DiNuzzo, who has spent more than 26 years in leadership positions in the life and analytical science industries. Fran DiNuzzo commented, “I am excited by the opportunity to continue leading Strategic Diagnostics. SDI has a portfolio of valuable customers, core capabilities, new technologies, and capable employee’s that form the basis for a strong and growing business. I look forward to working with our team to deliver solid business results.”
SDI is one of the largest commercial manufacturers of antibodies in the United States, with the ability to combine the power of Genomic Antibody Technology with the expertise necessary to service the broad needs of their customers in the pharmaceutical, biotechnology and academic research markets. The Company is already in the process of taking a focused look at how to best move forward with the Genomic Antibody Technology in order to enable leading life science companies to advance their work in a wide range of drug and biomarker research and discovery initiatives. SDI also continues to have excellent opportunities to generate growth in several industrial markets utilizing novel phage technology in combination with core competencies in antibody design and assay development.
Let us hear your thoughts below:
